Publications

 

Publications from the nanomedicine research group:

Research articles

  1. Førde JL, Herfindal L, Myhr KM, Torkildsen Ø, Mollnes TE, Skrede S. (2023). Ocrelizumab and ofatumumab, but not rituximab, trigger complement induction in vitro. Int Immunopharmacol. 124(Pt B):111021. doi: 10.1016/j.intimp.2023.111021.
  2. Bjørnstad R, Reiten IN, Knudsen KS, Schjøtt J, Herfindal L. (2022). A liposomal formulation of simvastatin and doxorubicin for improved cardioprotective and anti-cancer effect. Int J Pharm. 629:122379. doi: 10.1016/j.ijpharm.2022.122379.
    Here we developed a liposomal formulation with simvastatin and doxorubicin, which reduces the cardiotoxic effect of doxorubicin, while enhancing the anti-cancer effect.
  3. Førde JL, Reiten IN, Fladmark KE, Kittang AO, Herfindal L. (2022). A new software tool for computer assisted in vivo high-content analysis of transplanted fluorescent cells in intact zebrafish larvae. Biol Open. 11(12):bio059530. doi: 10.1242/bio.059530. This work demonstrate how it is possible to estimate tumour burden in zebrafish transplanted with human leukaemia cells, using a self-written software.

  4. Alhourani A, Førde JL, Nasrollahzadeh M, Eichacker LA, Herfindal L, Hagland HR. (2022). Graphene-based phenformin carriers for cancer cell treatment: a comparative study between oxidized and pegylated pristine graphene in human cells and zebrafish. Nanoscale Adv. 4(6):1668-1680. doi: 10.1039/d1na00778e.

  5. Alhourani A, Førde JL, Eichacker LA, Herfindal L, Hagland HR. (2021). Improved pH-Responsive Release of Phenformin from Low-Defect Graphene Compared to Graphene Oxide. ACS Omega. 2021 https://doi.org/10.1021/acsomega.1c03283. This paper demonstrates how PEGylated pristine graphene nanosheets are superior to graphene oxide in adsorption and controlled release of an anti-cancer drug.
  6. Wang Z, Landy D, Sizun C, Cézard C, Solgadi A, Przybylski C, de Chaisemartin L, Herfindal L, Barratt G, Legrand FX. (2020). Cyclodextrin complexation studies as the first step for repurposing of chlorpromazine. Int J Pharm. 2020 Jun 30;584:119391. doi: 10.1016/j.ijpharm.2020.119391. Here, our collaborators at Univ. Paris-Saclay have designed a cyclodextrin-based nanocarrier for transportation of chlorpromazine. We want to use chlorpromazine to treat AML, but need to avoid the drug to enter the brain.
  7. Serkland TT, Schjøtt J, Berg JA, Herfindal L, Riedel B, Skrede S. (2019). Distribution of Psychotropic Drugs Into Lipoproteins. Ther Drug Monit. 2019 Dec;41(6):766-771. doi: 10.1097/FTD.0000000000000660. This work describes how our own nanocarriers, the lipoproteins, transport drugs in the blood. Our findings will help understand how drugs distribute in the body, not just passively, but also by active uptake of lipoproteins in tissues.

  8. Singh A, Myklebust NN, Furevik SMV, Haugse R, Herfindal L. (2019). Immunoliposomes in Acute Myeloid Leukaemia Therapy: An Overview of Possible Targets and Obstacles. Curr Med Chem. 2019;26(28):5278-5292. doi: 10.2174/0929867326666190517114450. In this review-article, we discuss the possibility to improve treatment of acute myeloid leukaemia using liposomes decorated with antibody or antibody fragments. We also propose some possible target molecules on the AML cells and AML stem cells, as well as how to cope with the different constituents in the bone marrow environment.

  9. Prandina A, Herfindal L, Radix S, Rongved P, Døskeland SO, Le Borgne M, Perret F. (2018). Enhancement of iodinin solubility by encapsulation into cyclodextrin nanoparticles. J Enzyme Inhib Med Chem. 2018 Dec;33(1):370-375
    An external file that holds a picture, illustration, etc. Object name is IENZ_A_1421638_F0002_C.jpg

  10. Bezem MT, Johannessen FG, Jung-Kc K, Gundersen ET, Jorge-Finnigan A, Ying M, Betbeder D, Herfindal L, Martinez A (2018). Stabilization of Human Tyrosine Hydroxylase in Maltodextrin Nanoparticles for Delivery to Neuronal Cells and Tissue. Bioconjug Chem. 2018 Feb 21;29(2):493-502. This paper describes how maltodextrin nanoparticles can carry functional enzymes and transport the enzymes into the cells. We also described how these nanoparticles can be injected into the brain of mice, and in the future, these can be used to treat neurodegenerative diseases.

  11. Evensen L, Johansen PL, Koster G, Zhu K, Herfindal L, Speth M, Fam SB, Fenaroli F, Prasmickaite L, Mælandsmo G, Snaar-Jagalska E, Griffiths G (2015). Zebrafish as a model system for characterization of nanoparticles against cancer. Nanoscale 8(2), 862-77 (doi: 10.1039/c5nr07289a). In this paper, the group of Gareth Griffiths demonstrate how we can use zebrafish embryo to trace nanoparticles in real-time, and also how nanoparticle material and surface modifications influence circulation time and uptake by macrophages.Graphical abstract: Zebrafish as a model system for characterization of nanoparticles against cancer
  12. Sauvage F, Barratt G, Herfindal L, Vergnaud-Gauduchon J (2015):The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status. Curr Pharm Biotechnol 17(1), 30-41. In this review we discuss how nanocarriers can be used to improve therapy of acute myeloid leukaemia. This non-operable cancer is associated with heavy chemotherapy and poor outcome, but still only a few nano-sized drug formulations are being developed.
  13. Myhren L, Nilssen I, Nicolas V, Døskeland SO, Barrat G, Herfindal L (2014): Multi-functional liposomes containing daunorubicin and emetine against acute myeloid leukemia. Eur J Pharm Biopharm 88(1):186-93. We have developed a liposomal drug formulation, where we have encapsulated the two drugs emetine and daunorubicine in liposomes coated with PEG for “stealth” ability, and folate on the surface to target leukaemia cells. This formulation were particularly efficient against acute myeloid leukaemia in in vitro experiments.Basic RGB
  14. Oftedal L, Myhren L, Jokela J, Gausdal G, Sivonen K, Døskeland SO, Herfindal L# (2012): The lipopeptide toxins Anabaenolysin A and B target biological membranes in a cholesterol-dependent manner. BBA Biomembranes 1818(12):3000-9. Here, we used liposomes with or without cholesterol to determine the mechanism of action of a biodetergent isolated from a cyanobacterium.Graphical
  15. Rahman MA, Brekke J, Arnesen V, Hannisdal MH, Navarro AG, Waha A, Herfindal L, Rygh CB, Bratland E, Brandal P, Haasz J, Oltedal L, Miletic H, Lundervold A, Lie SA, Goplen D, Chekenya M. Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. Immun Inflamm Dis. 2020 Sep;8(3):342-359. doi: 10.1002/iid3.315
  16. Solum E, Hansen TV, Aesoy R, Herfindal L. (2020). New CDK8 inhibitors as potential anti-leukemic agents – Design, synthesis and biological evaluation.
     Bioorg Med Chem. 2020 May 15;28(10):115461. doi: 10.1016/j.bmc.2020.115461.
  17. Shishido TK, Popin RV, Jokela J, Wahlsten M, Fiore MF, Fewer DP, Herfindal L, Sivonen K. (2019). Dereplication of Natural Products with Antimicrobial and Anticancer Activity from Brazilian Cyanobacteria. Toxins (Basel). 12(1):12. doi: 10.3390/toxins12010012.
  18. Sivertsen Åsrud K, Pedersen L, Aesoy R, Muwonge H, Aasebø E, Nitschke Pettersen IK, Herfindal L, Dobie R, Jenkins S, Berge RK, Henderson NC, Selheim F, Døskeland SO, Bakke M. (2019). Mice depleted for Exchange Proteins Directly Activated by cAMP (Epac) exhibit irregular liver regeneration in response to partial hepatectomy.
    Sci Rep. 9(1):13789. doi: 10.1038/s41598-019-50219-8.
  19. Humisto A, Jokela J, Teigen K, Wahlsten M, Permi P, Sivonen K, Herfindal L. (2019). Characterization of the interaction of the antifungal and cytotoxic cyclic glycolipopeptide hassallidin with sterol-containing lipid membranes. Biochim Biophys Acta Biomembr. 2019 Aug 1;1861(8):1510-1521. doi: 10.1016/j.bbamem.2019.03.010.
  20. Serkland TT, Schjøtt J, Berg JA, Herfindal L, Riedel B, Skrede S. (2019). Distribution of Psychotropic Drugs Into Lipoproteins. Ther Drug Monit. 2019 Dec;41(6):766-771. doi: 10.1097/FTD.0000000000000660.
  21. Ibrahim AHH, Herfindal L, Rathe B, Andersen HL, da Silva Almeida T JRG, Fossen T (2019). A novel poly-oxygenated flavone glucoside from aerial parts of the Brazilian plant Neoglaziovia variegata (Bromeliaceae). Heliyon 5 (3), e01369
  22. Bjørnstad R, Aesoy R, Bruserud Ø, Brenner AK, Giraud F, Dowling TH, Gausdal G, Moreau P, Døskeland SO, Anizon F, Herfindal L (2019). A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia. Mol Cancer Ther. 2019 Mar;18(3):567-578.
  23. Calisto RS, Sæbø EF, Storesund JE, Øvreås L, Herfindal L, Lage OM (2018). Anticancer activity in Planctomycetes. Frontiers in Marine Science 5, 499
  24. Prandina A, Herfindal L, Radix S, Rongved P, Døskeland SO, Le Borgne M, Perret F. (2018). Enhancement of iodinin solubility by encapsulation into cyclodextrin nanoparticles. J Enzyme Inhib Med Chem. 2018 Dec;33(1):370-375
  25. Bezem MT, Johannessen FG, Jung-Kc K, Gundersen ET, Jorge-Finnigan A, Ying M, Betbeder D, Herfindal L, Martinez A (2018). Stabilization of Human Tyrosine Hydroxylase in Maltodextrin Nanoparticles for Delivery to Neuronal Cells and Tissue. Bioconjug Chem. 2018 Feb 21;29(2):493-502.
  26. Nygaard G, Herfindal L, Asrud KS, Bjørnstad R, Kopperud RK, Oveland E, Berven FS, Myhren L, Hoivik EA, Lunde THF, Bakke M, Døskeland SO, Selheim F. Epac1-deficient mice have bleeding phenotype and thrombocytes with decreased GPIbβ expression. Sci Rep. 2017 7(1):8725
  27. Viktorsson EÖ, Melling Grøthe B, Aesoy R, Sabir M, Snellingen S, Prandina A, Høgmoen Åstrand OA, Bonge-Hansen T, Døskeland SO, Herfindal L, Rongved P. Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives. Bioorg Med Chem. 2017 25(7), 2285-2293
  28. Vu M, Herfindal L, Juvik OJ, Vedeler A, Haavik S, Fossen T (2016). Toxic aromatic compounds from fruits of Narthecium ossifragum L. Phytochemistry 132, 76-85. (doi: 10.1016/j.phytochem.2016.09.010)
  29. Humisto A, Herfindal L, Jokela J, Bjørnstad R, Choudhury R, Sivonen K (2016). Cyanobacteria as a Source for Novel Anti-Leukemic Compounds. Curr Pharm Biotechnol 17(1), 78-91
  30. Evensen L, Johansen PL, Koster G, Zhu K, Herfindal L, Speth M, Fam SB, Fenaroli F, Prasmickaite L, Mælandsmo G, Snaar-Jagalska E, Griffiths G (2016). Zebrafish as a model system for characterization of nanoparticles against cancer. Nanoscale 8(2), 862-77 (doi: 10.1039/c5nr07289a)
  31. Giraud F, Bourhis M, Ebrahimi E, Herfindal L, Døskeland SO, Anizon F, Moreau P (2015). Synthesis and biological activities of diversely substituted N-1,N-10-bridged pyrrolo[2,3-a]carbazole-3-carbaldehydes. Eur J Med Chem 23(22), 7313-23
  32. Bouaziz Z, Issa S, Gentili J, Gratz A, Bollacke A, Kassack M, Jose J, Herfindal L, Gausdal G, Doskeland SO, Mullié C, Sonnet P, Desgrouas C, Taudon N, Valdameri G, Di Pietro A, Baitiche M, Le Borgne M (2015): Biologically active carbazole derivatives: Focus on oxazinocarbazoles and related compounds. J Enz Inhib Med Chem 30(2), 180-8.
  33. Giraud F, Bourhis M, Herfindal L, Døskeland SO, Anizon F, Moreau P (2014). New N-1/N-10 bridged pyrrolo[2,3-α]carbazole-3-carbaldehydes as Pim kinase modulators: Effect of the bridge on the kinase inhibitory potency. Bioorg Chem (doi: 10.1016/j.bioorg.2014.09.004).
  34. Liu L, Jokela J, Herfindal L, Wahlsten M, Sinkkonen J, Permi P, Fewer D, Døskeland SO, Sivonen K (2014). 4-methylproline guided natural product discovery: co-occurrence of 4-hydroxy- and 4-methylprolines in nostoweipeptins and nostopeptolides. ACS Chem Biol (doi: 10.1021/cb500436p).
  35. Nygaard G, Herfindal L, Kopperud R, Aragay AM, Holmsen H, Døskeland SO, Kleppe R, Selheim F (2014): Time-dependent inhibitory effects of cGMP-analogues on thrombin-induced platelet-derived microparticles formation, platelet aggregation, and P-selectin expression. Biochem Biophys Res Commun 449(3), 357-363.
  36. Myhren L, Nilssen I, Nicolas V, Døskeland SO, Barrat G, Herfindal L (2014): Multi-functional liposomes containing daunorubicin and emetine against acute myeloid leukemia. Eur J Pharm Biopharm 88(1):186-93.
  37. Liu L, Herfindal L, Jokela J, Shishido T, Wahlsten M, Døskeland SO, Sivonen K (2014): Cyanobacteria from terrestrial and marine sources contain apoptogens able to overcome chemoresistance in acute myeloid leukemia cells. Mar Drugs 14(4), 2036-2053.
  38. Herfindal L, Krakstad C, Myhren L, Hagland H, Kleppe R, Døskeland SO (2014): Increasing number of ring-containing substituents in cyclic nucleotides is associated with inhibition of the hepatocyte transporters OATP 1B1 and 1B3. PLoSONE 9(4):e94926.
  39. Bouaziz Z, Issa S, Gentili J, Gratz A, Bollacke A, Kassack M, Jose J, Herfindal L, Gausdal G, Doskeland SO, Mullié C, Sonnet P, Desgrouas C, Taudon N, Valdameri G, Di Pietro A, Baitiche M, Le Borgne M (2014): Biologically active carbazole derivatives: Focus on oxazinocarbazoles and related compounds. J Enz Inhib Med Chem (doi:10.3109/14756366.2014.899594).
  40. Prestegard S, Knutsen G, Herfindal L (2014): Adenosine levels and growth in the diatom Phaeodactylum tricornutum (Bacillariophyceae): Effect of light, temperature, salinity and nitrate. Diatom Res 29(4), 361-369.
  41. Sletta H, Degnes KF, Herfindal L, Klinkenberg G, Fjærvik E, Zahlsen K, Brunsvik A, Nygaard G, Aachmann FL, Ellingsen TE, Døskeland SO, Zotchev SB (2014): Anti-microbial and cytotoxic 1,6-dihydroxyphenazine-5,10-dioxide (iodinin) produced by Streptosporangium sp. DSM 45942 isolated from the fjord sediment. Appl Microbiol Biotechnol 98(2):603-10.
  42. Herfindal L, Nygaard G, Kopperud R, Krakstad C, Døskeland SO, Selheim F (2013): Off-target effect of the Epac agonist 8-pCPT-2′-O-Me-cAMP on P2Y12 receptors in blood platelets. Biochem Biophys Res Commun 437(4), 603–608.
  43. Herfindal L, Gjertsen BT, Døskeland SO, Gausdal G (2013) Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen. BMC Cancer 13:341. doi: 10.1186/1471-2407-13-341.
  44. Myhren L, Nygaard G, Gausdal G, Teigen K, Sletta H, Selheim F, Bruserud Ø, Døskeland SO, Herfindal L (2013): Iodinin (1,6-dihydroxyphenazine 5,10 dioxide) is a potent anti-leukemic compound with high selectivity towards AML cell lines and patient blasts. Marine Drugs 11(2), 332-349.
  45. Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Herfindal L, Kleppe R, Rouhee N, McCormack E, Havemann U, Schwede F, Bruserud Ø, Gjertsen BT, Lanotte M, Ségal-Bendirdjian E, Døskeland SO (2013): Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death Dis 4: e516; doi:10.1038/cddis.2013.39.
  46. Oftedal L, Myhren L, Jokela J, Gausdal G, Sivonen K, Døskeland SO, Herfindal L (2012): The lipopeptide toxins Anabaenolysin A and B target biological membranes in a cholesterol-dependent manner. BBA Biomembranes 1818(12):3000-9.
  47. Jokela J, Oftedal L, Herfindal L, Permi P, Wahlsten M, Døskeland SO, Sivonen K (2012): Anabaenolysins, novel cytolytic lipopeptides from benthic Anabaena cyanobacteria. PLoS ONE 7(7) e41222.
  48. Herfindal L, Myhren L, KleppeR, Krakstad C, Selheim F, Jokela J, Sivonen K, DøskelandSO (2011): Ncp-M1: A potent, nontoxic inhibitor of the hepatocyte transporters OATP1B3 and 1B1. Mol Pharm 8(2):360-7.
  49. Oftedal L, Skjærven KH, Coyne RT, Edvardsen B, Rohrlack T, Skulberg OM, Døskeland SO, Herfindal L (2011): The apoptosis inducing activity towards leukaemia and lymphoma cells in a cyanobacterial culture collection is not associated with mouse-bioassay toxicity. J Industrial Microbiol Biotechnol 38(4):489-501.
  50. Oftedal L, Selheim F, Wahlsten M, Sivonen K, Døskeland SO Herfindal L (2010): Compounds from benthic cyanobacteria synergise with daunorubicin to induce apoptosis in leukaemia cells, but not in normal cardiomyoblasts. Mar Drugs 8(10):2659-72.
  51. Jokela J, Herfindal L, Wahlsten M, Permi P, Selheim F, Vasconcelos V, Døskeland SO, Sivonen K (2010): A novel cyanobacterial nostocyclopeptide is a potent antitoxin against microcystin. Chembiochem 11(11):1594-9.
  52. Prestegard SK, Oftedal L, Coyne RT, Nygaard G, Skjaerven KH, Knutsen G, Døskeland SO, Herfindal L (2009): Marine benthic diatoms contain compounds able to induce leukemia cell death and modulate blood platelet activity. Mar Drugs 7(4):605-23.
  53. Jørgensen H, Degnes KF, Sletta H, Fjaervik E, Dikiy A, Herfindal L, Bruheim P, Klinkenberg G, Bredholt H, Nygård G, Døskeland SO, Ellingsen TE, Zotchev SB (2009): Biosynthesis of macrolactam BE-14106 involves two distinct PKS systems and amino acid processing enzymes for generation of the aminoacyl starter unit. Chem Biol 16(10):1109-21.
  54. Herfindal L, Kasprzykowski F, Schwede F, Łankiewicz L, Fladmark KE, Łukomska J, Wahlsten M, Sivonen K, Grzonka Z, Jastorff B, Døskeland SO (2009): Acyloxymethyl esterification of nodularin-R and microcystin-LA produces inactive protoxins that become reactivated and produce apoptosis inside intact cells. J Med Chem 52(18): 5758-62.
  55. Martins RF, Ramos MF, Herfindal L, Sousa JA, Skaerven K, Vasconcelos VM (2008): Antimicrobial and cytotoxic assessment of marine cyanobacteria – Synechocystis and Synechococcus. Mar Drugs. 6(1):1-11.
  56. Krakstad C, Herfindal L, Gjertsen BT, Bøe R, Fladmark KE, Døskeland SO (2006): CaM-kinaseII dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation. Cell Death Differ 13:1191-1202.
  57. Selheim F, Herfindal L, Martins R, Vasconcelos V, Døskeland SO (2005): Neuro-apoptogenic and blood platelet targeting toxins in benthic marine cyanobacteria from the Portuguese coast. Aquatic Toxicol 74: 294-306.
  58. Herfindal L, Oftedal L, Selheim F, Wahlsten M, Sivonen K, Døskeland SO (2005): A high proportion of benthic Baltic Sea cyanobacterial isolates contain inducers of isolated rat hepatocyte apoptosis. Toxicon 46: 252-260.

Review articles, editorials, and book chapters

  1. Fewer DP, Jokela J, Heinilä L, Aesoy R, Sivonen K, Galica T, Hrouzek P, Herfindal L. (2021). Chemical diversity and cellular effects of antifungal cyclic lipopeptides from cyanobacteria. Physiol Plant. 2021 Oct;173(2):639-650. doi: 10.1111/ppl.13484.
  2. Skjånes K, Aesoy R, Herfindal L, Skomedal H. (2021). Bioactive peptides from microalgae: Focus on anti-cancer and immunomodulating activity.  Physiol Plant. 2021 Oct;173(2):612-623. doi: 10.1111/ppl.13472.
  3. Allahverdiyeva Y, Aro EM, van Bavel B, Escudero C, Funk C, Heinonen J, Herfindal L, Lindblad P, Mäkinen S, Penttilä M, Sivonen K, Skogen Chauton M, Skomedal H, Skjermo J. (2021) NordAqua, a Nordic Center of Excellence to develop an algae-based photosynthetic production platform. Physiol Plant. 2021 Oct;173(2):507-513. doi: 10.1111/ppl.13394.
  4. Singh A, Myklebust NN, Furevik SMV, Haugse R, Herfindal L. (2019). Immunoliposomes in Acute Myeloid Leukaemia Therapy: An Overview of Possible Targets and Obstacles. Curr Med Chem. 2019;26(28):5278-5292. doi: 10.2174/0929867326666190517114450.
  5. Selheim F, Herfindal L (2016). Editorial: Toward Personalized Treatment for Acute Myeloid Leukemia. Curr Pharm Biotechnol 17(1), 4-5
  6. Sauvage F, Barratt G, Herfindal L, Vergnaud-Gauduchon J (2016). The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status. Curr Pharm Biotechnol 17(1), 30-41
  7. Kleppe R, Herfindal L, Døskeland SO (2015). Cell Death Inducing Microbial Protein Phosphatase Inhibitors–Mechanisms of Action. Mar Drugs 13(10):6505-20.
  8. Kleppe R, Herfindal L, Madsen L, Haavik J, Selheim F, Døskeland SO (2015): Cyclic AMP and cGMP recognition and selectivity – guidelines for the use of cAMP analogs. In Xiaodong Cheng (ed): Cyclic Nucleotide Signaling. CRC Press, Taylor and Francis.
  9. Herfindal L, Selheim F (2006): Microcystin produces disparate effects on liver cells in a dose dependent manner. Mini Rev Med Chem 6: 279-285.
  10. Gausdal G, Krakstad C, Herfindal L, Døskeland SO (2006): Serine/Threonine phosphatases and apoptosis. In Rakesh Srivastava (ed): Apoptosis, Cell Signaling, and Human Disease: Molecular Mechanisms. The Human Press, Inc.
  11. Bruserud Ø, Glenjen N, Gjertsen BT, Herfindal L, Døskeland SO (2002): Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells. Exp Opin Biol Ther 2:197-210.

 

Leave a Reply

Your email address will not be published. Required fields are marked *